flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 clinical (funded by Novo Nordisk): showed 24% reduction in the risk of disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators Preventing chronic kidney disease and

Description

Can nausea be a sign that my dose is too high

If pancreatitis is suspected, Wegovy should be discontinued and appropriate diagnostic tests performed urgently Gallbladder problems : Rapid weight loss increases risk of gallstone formation, with cholelithiasis reported in approximately 1.6% of Wegovy users Intestinal obstruction/ileus : Cases have been reported in post-marketing surveillance, particularly in patients with pre-existing GI conditions Management strategies recommended by healthcare professionals include: Eating smaller, more frequent meals rather than large portions Avoiding high-fat, spicy, or heavily processed foods Staying well-hydrated, particularly if experiencing diarrhoea or vomiting, to prevent dehydration and potential acute kidney injury Not lying down immediately after eating to minimise reflux Ensuring adequate fibre intake to prevent constipation Taking the medication on the same day each week to maintain steady levels Most GI side effects improve over time as the body adjusts to the medication, typically becoming less troublesome after 4-8 weeks at each dose level

Results: Nearly all Weight Loss, Hormone, and Sexual Health Therapies secured positions in the top 5 on Google search results

The Benefits of Semaglutide Significant Weight Loss: Studies have shown that Semaglutide can lead to an average weight loss of 5-15% of the initial body weight, depending on the dosage and duration of treatment

However, the speed at which these changes occur with GLP-1 therapies suggests that at least part of the effect may be independent of weight loss or glucose control